AORT20251017P12.5
AORT Oct 17 2025 12.50 Put (AORT251017P00012500)
option OPRA

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife's bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife's cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife's biofoam® surgica